Aspargo Labs’ business model is repeatable and applies our proprietary technology to the world’s most meaningful compounds and brands.
Current and near-term projects have strong IP protection through 2036, including Oral Suspension for Sildenafil (VIAGRA®) through 2036.
Multiple patents granted for future digitally connected drug delivery device.
Aspargo Labs has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) as part of the process to become a publicly traded company. This filing includes details about the company’s business, financials, and the proposed listing of our shares on the New York Stock Exchange.
You can view the filed S-1 registration statement on the SEC’s database HERE.
Stay informed with our latest updates:
Disrupting Erectile Dysfunction (ED) Market With Oral Spray Aspargo Laboratories, Inc. to leverage Laboratorio SIDUS’ ED market position to launch Sildenafil Oral Spray in Argentina
Disrupting Erectile Dysfunction (ED) Market With Oral Spray Aspargo Laboratories, Inc. and Taiba Healthcare Group to launch Sildenafil Spray in Middle East region via exclusive
Acquisition significantly boosts Aspargo’s presence as a global biopharmaceutical company in erectile dysfunction Company acquires international rights to Sildenafil Oral Spray from Farmalider, S.A. for
Disrupting Erectile Dysfunction (ED) Market with Oral Spray Aspargo Laboratories, Inc. and Laboratorios Vanquish, S.A. to jointly launch Sildenafil Oral Spray in Mexico via exclusive
Immediate Revenue And Expansion Of Global Footprint Acquisition transforms Aspargo into a revenue producing company European market entry positions Aspargo for commercialization of Sildenafil Oral
Aspargo Laboratories, Inc. Announces Successful Completion of Pre-IND Meeting with FDA on Sildenafil Oral Spray for the Treatment of Erectile Dysfunction Alignment with FDA to